June 5, 2025 - Zurich, Switzerland | Orlando, Florida
InSphero, the global leader in industry-ready 3D in vitro solutions for preclinical research, announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems. This partnership will provide pharmaceutical and biotechnology companies with bespoke, integrated solutions spanning the entire drug development pipeline from early-stage screening to functional assessments in later stages of the development.
By combining InSphero’s highly scalable spheroid and organoid platforms with Hesperos’ single and multi-tissue systems, including central and peripheral nervous system, cardiac and skeletal muscle, liver, kidney, spleen, and barrier tissues, researchers can now benefit from a growing portfolio of physiologically relevant models tailored to a wide range of applications in discovery and safety including on- and off-target toxicity, efficacy via clinically relevant functional readouts, and PK/PD predictions. This continuum ranges from InSphero’s high-throughput models to develop and identify the best candidate for scale up to Hesperos’ high contrast screening models that have resulted in authorization of multiple repurposed drugs into Phase II clinical trials.
The collaboration is non-exclusive and founded on a long-standing scientific respect for each other’s technologies and complementary strengths. Dr. Jan Lichtenberg, CEO and Co-founder at InSphero commented, “Our customers are increasingly looking for seamless solutions that combine scalability and biological complexity. By partnering with Hesperos, we can offer just that: flexibility, depth, and scientific excellence across the entire value chain.”
Prof. James Hickman, Co-Founder and Chief Scientist, Hesperos Inc., added, “At Hesperos, we have always believed in the power of collaboration to advance human-relevant science. Partnering with InSphero enables us to bridge early screening with systems-level functional assessment, creating a new benchmark for in vitro testing platforms.”
Meet both teams at the MPS Summit 2025, June 9-13, and learn more about their common efforts in scalable and human-relevant 3D in vitro drug discovery.
